Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Has Sought Advice On Compulsory Licensing For Vertex’ Orkambi

Executive Summary

Pressure on Vertex over access to its cystic fibrosis drug Orkambi in England is mounting after the parliamentary undersecretary for health admitted the government has already taken advice on compulsory licensing of the product.

You may also be interested in...



UK Opposition Party Wants Compulsory Licenses For ‘Extortionate’ Medicines

The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.

Compulsory License On Table In UK For Orkambi

The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.

Bio Industry Warns UK Orkambi Inquiry Against Publishing Confidential Price Information

Vertex and bioindustry groups have called on a UK inquiry investigating the availability of the cystic fibrosis drug Orkambi on the National Health Service not to publish confidential information.

Topics

UsernamePublicRestriction

Register

PS124699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel